abstract |
The present invention relates to a pharmaceutical composition comprising (a) a phosphatidylinositol 3-kinase inhibitor or a pharmaceutically acceptable salt thereof, and (b) a pharmaceutically acceptable salt thereof, for the simultaneous, separate or sequential administration for the treatment of a proliferative disease, ) A pharmaceutical combination comprising at least one c-Met receptor tyrosine kinase inhibitor or a pharmaceutically acceptable salt thereof; A pharmaceutical composition comprising such a combination; A method of treating a subject having a proliferative disease, comprising administering the combination to a subject in need of treatment for a proliferative disorder; To the use of such a combination for the treatment of proliferative disorders. |